Yale University professor claims that semaglutide can delay aging
The research results released at the European Society of Cardiology conference show that GLP-1 drugs such as semaglutide have the potential to significantly delay the aging process in humans, leading to longer and healthier lives. This news has attracted widespread attention from the scientific community. Research has found that semaglutide (Wegovy and Ozempic) can effectively reduce the risk of death in obese or overweight patients with cardiovascular disease. This article published in the flagship journal of the American College of Cardiology, JACC. It points out that the benefits of semaglutide far exceed expectations.
However, the latest research has found that Ozempic has a wider range of effects. The probability of death, whether due to cardiovascular problems or other reasons, has decreased among people taking this medication. Professor Harlan Krumholt from Yale University School of Medicine said, “The benefits of semaglutide far exceed our expectations. It not only prevents heart disease, but also helps improve overall health. This means that it may slow down the aging process of the human body
The study found that smeglutide can reduce the risk of death due to infection and cardiovascular disease risk.
This study was conducted in the Select trial in the United States. It involving 17604 overweight or obese subjects aged 45 years and over with cardiovascular disease but no diabetes. They were divided into two groups and treated with either semaglutide or placebo. Three years later, a follow-up survey found that the infection mortality rate in the medication group was significantly lower than that in the control group, and the risk of cardiovascular disease continued to decrease.
The significant reduction in non cardiovascular mortality, especially infection mortality, is astonishing. These research findings further confirm that overweight and obesity increase the risk of death from multiple causes. “It can be controlled through therapies such as semaglutide “said Benjamin Sirica, a Harvard University professor and lead author of the study.
Research has shown that semaglutide can significantly reduce the risk of cardiovascular events by 20%
Another study found that semaglutide can significantly reduce the risk of major adverse cardiovascular events (MACEs), including cardiovascular death, non fatal heart attacks, and non fatal strokes. This study is applicable to adults who have been diagnosed with cardiovascular disease and are overweight or obese. The initial body mass index is ≥ 27kg/m2, and there is no diabetes.
The SELECT experiment was conducted in over 800 locations in 41 countries/regions worldwide, recruiting a total of 17604 adults. The experimental results showed that compared with placebo, semaglutide can significantly reduce the risk of MACE by 20%. Moreover, this risk reduction effect remains stable for up to five years. In addition, cardiovascular mortality and all-cause mortality were reduced by 15% and 19%, respectively, and the comprehensive endpoint of heart failure was also reduced by 18%.
